PEN — Penumbra, Inc.

Summary of Penumbra's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $354.7 million, up 17.8% year-over-year (16.9% on a constant currency basis).
• U.S. Revenue: $275 million, a 21.5% increase year-over-year.
• Gross Margin: 67.8%, an expansion of 130 basis points from the prior year.
• Operating Income: $48.8 million (13.8% of revenue), compared to $40.3 million (13.4% of revenue) in Q3 2024.
• Adjusted EBITDA: $66.7 million (18.8% of total revenue), consistent with the previous year.
• Cash Position: Ended the quarter with $470.3 million in cash and no debt, an increase of $45.7 million sequentially.

2. Strategic Updates and Business Highlights

• Product Performance: Strong growth in the U.S. thrombectomy business (+18.5% YoY) and embolization/access business (+29.2% YoY), driven by the Ruby XL product and a dedicated sales team.
• International Growth: Total international revenue increased by 6.6% YoY, with improvements in regions outside of China.
• New Product Launches: Received FDA clearance for Lightning Bolt 16 and Lightning Flash 3.0, enhancing the CAVT technology portfolio.
• Clinical Trials: Positive results from the STORM-PE trial were presented, showing CAVT's superiority in treating pulmonary embolism, which is expected to drive adoption and change clinical practices.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised for the year to $1.375 billion to $1.380 billion, with U.S. thrombectomy growth projected at 20% to 21% for 2025.
• Margin Expectations: On track to achieve a gross margin of over 70% by the end of 2026, with operating margin expansion expected to outpace gross margin growth.

4. Bad News, Challenges, or Points of Concern

• Market Dynamics: The U.S. stroke market showed a slight decline, impacting overall growth in the thrombectomy segment.
• China Market Headwinds: While easing, challenges in the Chinese market persist, affecting international revenue growth.
• Operational Expenses: Total operating expenses increased to $191.6 million (54% of revenue), with SG&A expenses rising due to the expansion of the embolization sales team, which may pressure margins in the short term.

5. Notable Q&A Insights

• Thunderbolt FDA Review: The approval process is ongoing, with no additional testing required at this stage. The company remains optimistic but cautious about timelines.
• STORM-PE Impact: Strong physician interest in CAVT following STORM-PE results is expected to accelerate adoption, with non-interventionalists also looking to update hospital protocols.
• Embolization Growth: The dedicated embolization sales team has successfully driven significant revenue growth, and there is optimism about capturing further market share.
• Market Share vs. Growth: The company is gaining market share in the thrombectomy space, although the overall market growth has been variable, particularly in the stroke segment.

Overall, Penumbra reported strong financial results driven by robust product performance and strategic initiatives, while also navigating challenges in specific markets and operational expenses. The positive reception of clinical trial results is expected to bolster future growth prospects.